Pacing-Induced Cardiomyopathy: Incidence, Diagnosis, and Management
Permanent cardiac pacing protects patients from bradycardia, atrioventricular block, and pauses, yet right ventricular stimulation can create an electrical activation pattern that differs substantially from normal conduction. In susceptible patients, this ventricular dyssynchrony may lead to progressive left ventricular dysfunction, heart failure symptoms, and recurrent hospitalization. The resulting condition is commonly described as pacing-induced cardiomyopathy, or PICM.
PICM is clinically important because it can develop after an apparently successful pacemaker implantation and may be reversible when recognized early. Its frequency varies according to the definition used, the pacing burden, baseline ventricular function, lead position, duration of follow-up, and the underlying rhythm disorder. A careful assessment therefore requires more than a single ejection fraction measurement.
Modern management combines device programming, guideline-directed heart failure treatment, and selected use of cardiac resynchronization therapy or conduction system pacing. Understanding who is at risk and how to distinguish pacing-related decline from other causes of cardiomyopathy helps clinicians select an effective intervention.
Defining The Clinical Syndrome
There is no universally accepted diagnostic definition of PICM. A commonly used framework requires a reduction in left ventricular ejection fraction of at least 10 percentage points from a normal baseline, resulting in an ejection fraction below 50%, in the setting of substantial right ventricular pacing and no better alternative explanation. Some studies use a post-pacing ejection fraction below 45%, while others include a relative decline in global longitudinal strain before ejection fraction falls.
The amount of ventricular pacing matters, although no single threshold identifies every patient. A burden above 20% may increase risk, and a burden above 40% is frequently associated with a greater likelihood of ventricular dysfunction and heart failure. Patients with a high burden of paced beats, a wide paced QRS complex, pre-existing left ventricular impairment, or reduced native conduction reserve deserve closer surveillance.
PICM is a diagnosis of exclusion. Ischemic heart disease, uncontrolled hypertension, valvular disease, atrial tachyarrhythmia, infiltrative conditions, myocarditis, and tachycardia-mediated cardiomyopathy can produce a similar decline. The temporal relationship between pacemaker implantation and ventricular deterioration is useful, but it should not replace a complete clinical evaluation.
Incidence And Predisposing Factors
Reported incidence ranges from approximately 5% to 20% during the first several years after implantation, with variation reflecting different definitions and follow-up periods. The risk is often higher in cohorts with frequent right ventricular apical pacing and lower in populations with a substantial amount of intrinsic conduction. Subclinical remodeling may occur before symptoms or a conventional ejection fraction decline becomes apparent.
Several patient characteristics increase susceptibility. Male sex, older age, atrial fibrillation, chronic kidney disease, a history of heart failure, lower baseline ejection fraction, and a prolonged native or paced QRS duration have all been associated with risk in observational studies. A high cumulative pacing percentage is especially relevant in patients with complete atrioventricular block, because reducing pacing through programming may not be feasible.
The mechanism involves abnormal ventricular activation, delayed regional contraction, altered myocardial strain, and adverse remodeling. Right ventricular apical pacing can produce a left bundle branch block-like activation pattern, while septal or outflow tract positions do not consistently eliminate dyssynchrony. Research findings continue to evolve, and readers tracking emerging evidence can explore the journal’s arrhythmia collections for reviews and themed material on pacing and electrophysiology.
Recognizing And Confirming The Diagnosis
Symptoms may include exertional breathlessness, reduced exercise tolerance, fatigue, orthopnea, edema, or repeated admissions for congestion. Some patients remain asymptomatic and are identified through routine device follow-up or echocardiography. A new requirement for diuretics, rising natriuretic peptide levels, or a decline in functional capacity should prompt assessment even when the patient does not describe classic heart failure symptoms.
Device interrogation is central to the evaluation. Clinicians should document the percentage of atrial and ventricular pacing, paced and sensed QRS duration, programming mode, lower rate limit, atrioventricular delay, arrhythmia burden, lead integrity, and battery status. Stored electrograms may reveal atrial fibrillation, frequent ectopy, or ventricular arrhythmias that contribute to a fall in cardiac output.
Echocardiography usually provides the first objective evidence. Serial comparison of ejection fraction, left ventricular volumes, global longitudinal strain, right ventricular function, and valvular status can identify remodeling earlier than symptoms alone. Electrocardiography, laboratory testing, ischemia assessment, cardiac magnetic resonance imaging, or coronary angiography may be appropriate when the clinical picture suggests another cause.
A practical diagnosis combines three elements: meaningful ventricular dysfunction or remodeling, substantial pacing exposure, and exclusion of a competing explanation. The clinician should also consider whether the patient has heart failure with reduced, mildly reduced, or preserved ejection fraction, since treatment priorities and device indications may differ across these phenotypes.
Comparing Pacing And Resynchronization Options
The most appropriate device strategy depends on the indication for pacing, expected pacing burden, ventricular function, QRS morphology, venous anatomy, comorbidities, and local expertise. Conventional right ventricular pacing remains suitable for many patients, particularly when ventricular pacing will be infrequent. However, anticipated near-continuous pacing calls for greater attention to synchrony and long-term ventricular performance.
| Strategy | Main Physiologic Effect | Potential Advantages | Important Limitations |
|---|---|---|---|
| Right ventricular apical pacing | Produces nonphysiologic ventricular activation | Familiar technique, reliable implantation, broad availability | Greater dyssynchrony and PICM risk with high pacing burden |
| Right ventricular septal or outflow pacing | Attempts to reduce activation delay | May provide a narrower paced QRS in selected patients | Benefits are inconsistent and anatomy varies |
| His-bundle pacing | Activates the native His–Purkinje system | Can preserve near-normal ventricular activation | Higher implant complexity, threshold rise, and lead revision concerns |
| Left bundle branch area pacing | Captures the conduction system near the left bundle | Often produces efficient activation with stable thresholds | Long-term evidence and procedural standardization continue to develop |
| Biventricular cardiac resynchronization | Coordinates right and left ventricular activation | Established benefit in selected heart failure populations | Coronary sinus anatomy, phrenic stimulation, and nonresponse can limit results |
Conduction system pacing has expanded the options for avoiding or treating dyssynchrony. His-bundle pacing may restore physiologic activation when reliable capture is achieved, while left bundle branch area pacing has become increasingly attractive because it can offer a narrower QRS and practical implantation characteristics. Evidence supports individualized decision-making rather than assuming that one approach is optimal for every patient.
Management After Ventricular Decline
Initial management includes confirming the diagnosis, treating congestion, and introducing or optimizing guideline-directed medical therapy when appropriate. Depending on renal function, blood pressure, rhythm, and ejection fraction, this may include an angiotensin receptor-neprilysin inhibitor or renin-angiotensin system blocker, evidence-based beta-blocker, mineralocorticoid receptor antagonist, and sodium-glucose cotransporter-2 inhibitor. Loop diuretics are used to control fluid retention rather than to reverse remodeling.
Device reprogramming can reduce unnecessary right ventricular pacing in patients who retain reliable atrioventricular conduction. Longer atrioventricular delays, managed ventricular pacing algorithms, and appropriate mode selection may help, but these settings are unsuitable for everyone. Patients with complete heart block or advanced conduction disease may remain almost entirely dependent on ventricular pacing.
When PICM is established, upgrading to cardiac resynchronization therapy is a well-supported strategy for appropriately selected patients, especially those with symptomatic heart failure and significant left ventricular systolic impairment. Biventricular pacing can improve ejection fraction, ventricular volumes, symptoms, and functional capacity. Benefits may emerge over several months, so follow-up should include clinical assessment, device interrogation, and repeat imaging.
Conduction system pacing is an alternative upgrade strategy in experienced centers. It may be particularly useful when coronary sinus lead placement is unsuccessful, when a physiologic activation pattern is achievable, or when a patient requires lifelong high-burden pacing. Lead extraction, venous obstruction, infection risk, defibrillator requirements, and procedural frailty must be considered before any upgrade.
Building A Reliable Monitoring Strategy
Surveillance should begin with a documented pre-implant electrocardiogram and echocardiogram whenever feasible. Follow-up should record ventricular pacing percentage and compare cardiac imaging over time rather than relying on isolated measurements. Patients with a high pacing burden or additional risk factors may benefit from earlier post-implant echocardiography and periodic reassessment.
Remote monitoring can identify changes in pacing, atrial arrhythmia burden, lead performance, and sometimes heart failure indicators between clinic visits. It does not replace symptom review or imaging, but it enables earlier recognition of a deteriorating clinical trajectory. A widening paced QRS, increasing ventricular pacing percentage, or new atrial fibrillation should trigger a structured review.
Clinicians should also explain the warning signs that merit prompt evaluation, including rapidly worsening breathlessness, nocturnal symptoms, syncope, progressive edema, chest discomfort, or a marked reduction in exercise tolerance. Clear communication supports earlier referral to electrophysiology and heart failure services.
Practical measures for reducing preventable harm include:
- Identify the expected ventricular pacing burden before implantation and reassess it after programming changes.
- Obtain serial echocardiography when pacing is frequent, symptoms develop, or the paced QRS is markedly prolonged.
- Investigate ischemia, tachyarrhythmia, valvular disease, hypertension, and inflammatory or infiltrative conditions before assigning causality to pacing.
- Use device programming to preserve intrinsic conduction when clinically safe.
- Refer suitable patients with confirmed PICM for consideration of cardiac resynchronization or conduction system pacing.
Pacing-induced ventricular dysfunction is a potentially reversible complication rather than an inevitable consequence of permanent pacing. Timely recognition, coordinated electrophysiology and heart failure care, and a device strategy matched to the patient’s physiology can restore function and reduce symptoms. Clinicians seeking publication guidance, educational exchange, or journal-related assistance can use the Journal contact page to connect with the Journal of Arrhythmia team.